In Re: Savient Pharm , 283 F. App'x 887 ( 2008 )


Menu:
  •                                                                                                                            Opinions of the United
    2008 Decisions                                                                                                             States Court of Appeals
    for the Third Circuit
    7-2-2008
    In Re: Savient Pharm
    Precedential or Non-Precedential: Non-Precedential
    Docket No. 06-4864
    Follow this and additional works at: http://digitalcommons.law.villanova.edu/thirdcircuit_2008
    Recommended Citation
    "In Re: Savient Pharm " (2008). 2008 Decisions. Paper 920.
    http://digitalcommons.law.villanova.edu/thirdcircuit_2008/920
    This decision is brought to you for free and open access by the Opinions of the United States Court of Appeals for the Third Circuit at Villanova
    University School of Law Digital Repository. It has been accepted for inclusion in 2008 Decisions by an authorized administrator of Villanova
    University School of Law Digital Repository. For more information, please contact Benjamin.Carlson@law.villanova.edu.
    NOT PRECEDENTIAL
    UNITED STATES COURT OF APPEALS
    FOR THE THIRD CIRCUIT
    No. 06-4864
    IN RE: *SAVIENT PHARMACEUTICALS, INC.
    SECURITIES LITIGATION
    A.F.I.K. Holding SPRL, individually
    and as class representative,
    Appellant
    *(Amended in accordance with the Clerk's Order dated 03/26/07)
    APPEAL FROM THE UNITED STATES DISTRICT COURT
    FOR THE DISTRICT OF NEW JERSEY
    (D.C. Civil No. 02-cv-06048)
    District Judge: The Honorable Harold A. Ackerman
    Argued: June 24, 2008
    Before: SLOVITER, BARRY and ROTH, Circuit Judges
    (Opinion Filed: July 2, 2008)
    Frederick W. Gerkens, III, Esq. (Argued)
    Glancy, Binkow & Goldberg
    1430 Broadway, Suite 1603
    New York, NY 10018
    -AND-
    Lionel Z. Glancy, Esq.
    Robert M. Zabb, Esq.
    Glancy, Binkow & Goldberg
    1801 Avenue of the Stars
    Suite 311
    Los Angeles, CA 90067
    Counsel for Appellant
    Irwin H. Warren, Esq. (Argued)
    Weil, Gotshal & Manges
    767 Fifth Avenue, 27 th Floor
    New York, NY 10153
    -AND-
    Robert B. Kaplan, Esq.
    Greenberg Taurig
    200 Park Avenue
    P.O. Box 677
    Florham Park, NJ 07932
    Counsel for Appellees
    OPINION
    BARRY, Circuit Judge
    Plaintiff appeals the dismissal of its consolidated class action securities fraud
    complaint – the Second Amended Complaint – which charged Bio-Technology General
    Corp. (now Savient Pharmaceuticals, Inc.) and three of its senior officers with making
    false and misleading statements about the corporation’s financial performance in 1999,
    2000, and 2001. The District Court dismissed the Second Amended Complaint finding,
    2
    as it had with reference to the initial consolidated class action complaint, that scienter had
    not been adequately pled. Because plaintiff had already had “two large bites at the apple”
    and because further amendment would be futile, the dismissal was with prejudice. The
    predominant issue before us is whether the District Court erred in finding that the Second
    Amended Complaint failed to adequately plead scienter. Our review is plenary. Winer
    Family Trust v. Queen, 
    503 F.3d 319
    , 325 (3d Cir. 2007).
    We have reviewed the extensive record in this case; indeed, the complaints alone
    cover 120 and 162 pages, respectively. We have also reviewed the thorough, thoughtful
    and, in a word, superb opinions of the District Court, the first opinion comprehensively
    analyzing the numerous allegations of the initial consolidated class action complaint in
    light of the applicable law and laying out a road map for plaintiff to follow,1 and the
    second opinion explaining, after a close review of the Second Amended Complaint, the
    deficiencies that remained.2
    This is a case in which we need do no more than recognize the excellence of the
    District Court’s opinions; indeed, it would make little or no sense to even attempt to
    match the quality of that work. And so, substantially for the reasons set forth by the
    Honorable Harold A. Ackerman, we will affirm.
    1
    In re Bio-Technology General Corp. Sec. Litig., 
    380 F. Supp. 2d 574
    (D.N.J. 2005).
    2
    In re Bio-Technology General Corp. Sec. Litig., No. Civ. A. 02-6048, 
    2006 WL 3068553
    (D.N.J. Oct. 26, 2006).
    3
    

Document Info

Docket Number: 06-4864

Citation Numbers: 283 F. App'x 887

Filed Date: 7/2/2008

Precedential Status: Non-Precedential

Modified Date: 1/12/2023